An association between classical Hodgkin lymphoma (cHL) and mycosis fungoides (MF) or lymphomatoid papulosis has been reported in the literature. However, there can be considerable morphologic and immunophenotypic overlap between cHL and nodal involvement by CD30-positive T-cell lymphoproliferative disorders (CD30-T-LPD). To examine this potential association, biopsies from patients with a history of MF or primary cutaneous CD30-T-LPD and lymph node biopsies reported as either CD30-positive T-cell lymphoma (TCL) with Hodgkin-like cells or cHL were retrieved from the authors' institution. Of 11 cases identified, 10 were considered CD30-positive TCL with Hodgkin-like cells, whereas 1 was confirmed as cHL upon review. Five cases originally diagnosed as cHL were revised as CD30-positive TCL. Cases of CD30-positive TCL with Hodgkin-like cells showed a male predominance (M:F, 4:1) with a median age of 53 years (range, 44 to 72 y). Nearly all patients (9/10) initially presented with skin lesions. In 7/10 patients the draining lymph node was involved, whereas in 3 cases this could not be confirmed. Tumor cells morphologically resembled Hodgkin/Reed-Sternberg cells; they were uniformly strongly positive for CD30, and CD15 was expressed in 9/10 (90%) cases. A T-cell derivation was confirmed by T-cell antigen expression (7/10) and clonal rearrangement of T-cell receptor genes (9/10). In 3 cases a common T-cell clone was identified in skin and lymph node. B-cell markers (CD20/PAX5) were consistently negative. In 1 case the diagnosis of cHL followed by lymphomatoid papulosis was confirmed, with Hodgkin/Reed-Sternberg cells expressing PAX5, CD30, and CD15. In situ hybridization studies for Epstein Barr virus were negative. We show that cHL is less often associated with MF and primary cutaneous CD30-T-LPD than previously thought and that the coexpression of CD30 and CD15 in these TCLs may lead to a mistaken diagnosis of cHL. FIGURE 3. A, Lymph node (case 11) with features of cHL, mixed cellularity subtype. HRS cells are present in an inflammatory background. B, The HRS cells are positive for CD30 and PAX5 (inset), showing dim staining for the latter. C, The skin biopsy shows a wedge-shaped infiltrate sparing the epidermis composed of (D) large atypical cells in a background of histiocytes, small lymphocytes, and eosinophils.
M ycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (TCL) 26 accounting for almost 50% of all primary cutaneous TCLs. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders (CD30-T-LPD) are the second most common group of cutaneous TCLs. This group comprises a spectrum of diseases including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (c-ALCL), and cases with borderline features. 21 Histologic transformation of MF can occur, and involvement of extracutaneous sites such as lymph nodes are common. 24 There are rare reports of classical Hodgkin lymphoma (cHL) arising in patients with either MF or CD30-T-LPD. [2] [3] [4] 21 However, a true association has been debated, and in some instances the cHL has been said to be of T-cell derivation. 9 The differential diagnosis between cHL and nodal involvement by cutaneous CD30positive TCL with Hodgkin-like cells can be challenging and will influence the selection of therapy to be used. In an attempt to explore the nature of the association between cHL and MF or CD30-T-LPD, we undertook a study of cases in which a nodal diagnosis of cHL or a Hodgkin-like lesion was made in a patient with either MF or CD30-T-LPD. We analyzed the clinical, morphologic, immunophenotypic, and molecular findings of these 11 cases to explore the lineage of the neoplastic cells and to clarify their relationship to the cutaneous proliferation. We conclude that, although many such cases closely resemble cHL, the nodal disease in nearly all instances is a TCL derived from the cutaneous lesion.
MATERIALS AND METHODS

Tissue Specimens and Immunohistochemical Studies
Biopsies from patients with a suspected or reported diagnosis of nodal cHL and a diagnosis of either MF or CD30-T-LPD were retrieved from the archives of the Hematopathology Section of the National Cancer Institute (NCI) Laboratory of Pathology. The corresponding cutaneous lesions were retrieved for review as well. All biopsies were preserved as formalin-fixed paraffin-embedded (FFPE) tissue specimens. Immunohistochemical studies were conducted on FFPE tissue sections using a panel of monoclonal antibodies (CD30, CD15, PAX5, CD20, CD3, CD4, and CD8) according to previously published techniques. 5, 19 Histopathologic diagnosis was rendered by the authors according to the 2008 World Health Organization classification. 22 Categorization as nodal involvement by CD30-positive TCL required evidence of T-cell lineage using immunophenotypic and molecular criteria, whereas the diagnosis of cHL required evidence of the appropriate immunophenotype including CD30, CD15, and PAX5. The study was approved by the NCI Institutional Review Board.
In Situ Hybridization for Epstein Barr Virus (EBV)-encoded RNA (EBER)
In situ hybridization for EBER was performed on FFPE tissue sections using an FITC-labeled oligonucleotide probe supplied by Ventana on an automated stainer (Ventana-Benchmark, Tucson, AZ). Visualization was achieved using the ISH iView system with alkaline phosphatase and nitroblue tetrozolium and 5-bromo-4-chloro-3-indolyl phosphate substrate, with Fast red as contrast. A positive control was run with all cases and stained appropriately.
Molecular Studies
T-cell receptor g chain gene rearrangement studies (TRG) were conducted for all cases with available material. In brief, DNA was extracted using the QIAamp DNA FFPE Tissue Kit according to the manufacturer's instructions with minor modifications. PCR for detection of TRG was performed as described by Lawnicki et al 15 using primers that interrogate all of the known Vg family members and the Jg1/2, JP1/2, and JP joining segments. To allow for fluorescence detection, each joining region primer was covalently linked to a unique fluorescent dye. The products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer, and electropherograms were analyzed using GeneMapper software version 3.7 (ABI).
One case (case 6; Tables 1 and 2 ) was assessed in more detail by laser-assisted microdissection (LAM) of tumor cells and background T lymphocytes followed by molecular analysis. FFPE tissue sections of 5 mm were mounted on polyethylene naphthalate membrane glass slides (MDS Analytical Technologies, Sunnyvale, CA) and stained with Mayer's hematoxylin (Sigma-Aldrich, St Louis, MO) as previously described. 5 Tumor cells and background T lymphocytes were microdissected 
RESULTS
On the basis of immunophenotypic and molecular studies, nodal biopsies from 10 patients were classified upon review as CD30-positive TCL with Hodgkin-like cells. Five of these cases (cases 3, 4, 7, 8, and 10) had been previously diagnosed as cHL, but the diagnosis was revised upon further studies of the nodal lesion. In 1 case a diagnosis of cHL was confirmed on the lymph node, whereas the skin biopsy showed features of LyP.
CD30-positive TCL With Hodgkin-like Cells Morphologic and Immunophenotypic Features
Morphologically, the Hodgkin/Reed-Sternberg (HRS)like cells ranged in size from medium to large, had irregular nuclear contours, and vesicular chromatin ( Figs. 1A, B ). The cytoplasm and nucleoli of the HRS-like cells appeared more basophilic as compared with true HRS cells. Further, the nucleoli in the HRS-like cells tended to be multiple, whereas in cHL the HRS cells usually have single prominent eosinophilic nucleoli. The HRS-like cells formed clusters or sheets, often with a finely fibrotic background. Three cases showed more extensive fibrosis (cases 2, 7, and 8) mimicking cHL, nodular sclerosis subtype ( Fig. 2E ). Sinusoidal infiltration by tumor cells was a prominent feature (Figs. 1G, 2G). Some cases (4, 6, 8, 9, and 10) contained clusters of eosinophils and neutrophils, further mimicking cHL. The neoplastic cells in all cases were strongly positive for CD30 and CD15 (9/10, 90%) (Figs. 1E, F) and were negative for B-cell markers such as PAX5 and CD20 on the basis of immunohistochemical stains. T-cell markers (CD2, CD3, CD4, or CD8) were found to be positive in 7/10 cases ( Fig. 1H and Table 2 ).
The skin biopsies in these patients showed morphologic and immunophenotypic findings consistent with their respective diagnosis. Six cases were classified as LyP, 1 as c-ALCL, and 3 as MF (Fig. 2 ). All 7 CD30-T-LPD cases (LyP, c-ALCL) were positive for CD30 and negative for CD15 in the 4 cases studied. A T-cell phenotype was confirmed for the cutaneous lesions. One case expressed CD8, and in that instance the nodal lymphoma was also CD8 positive. All other cases evaluated were positive for CD3 and CD4. In 1 case of a patient with long-standing MF (case 10), the skin biopsies were not available for review.
Clinical Features
The majority of patients with CD30-positive TCL with Hodgkin-like cells were male (M:F, 4:1) with a median age of 53 years (range, 44 to 72 y) ( Table 1 ). Most cases (9/10) presented with skin lesions initially, followed by nodal involvement. In most patients many years elapsed between the onset of the cutaneous disease and the nodal lymphoma, and the extent of the cutaneous disease was variable. For the 3 patients with MF, skin lesions were present for many years, up to 20 years in 1 patient. The duration of the cutaneous disease was more variable for the 7 patients with LyP/c-ALCL. In 1 patient (case 8) the interval was only 1 year, with minimal cutaneous lesions that had been largely overlooked at the time of lymph node biopsy. In 1 patient (case 7), the nodal disease preceded clinical evidence of cutaneous lesions. In 7/10 patients the draining lymph node proximate to a dominant cutaneous lesion was involved, whereas in 3 cases generalized skin disease was present, precluding the establishment of a relationship.
cHL and LyP Clinical, Morphologic, and Immunophenotypic Features
The patient (case 11; Tables 1 and 2) was a 73-yearold man with a history of cHL in long-term remission. He also had a history of nummular eczema. He presented with papular/nodular lesions on the forearm and buttocks, which showed focal ulceration and crusting. The forearm lesion was excised. Two months later he was noted to have bilateral iliac lymphadenopathy, leading to a lymph node biopsy and a diagnosis of recurrent cHL.
The lymph node showed complete architectural effacement with scattered large atypical cells with irregular nuclear contours, vesicular chromatin, and prominent eosinophilic nucleoli, consistent with HRS cells (Fig. 3A) . The background showed numerous small lymphocytes and epithelioid histiocytes. The HRS cells were positive for CD30, weakly positive for PAX5, and focally positive for CD15 ( Fig. 3B) . Other B-cell-associated antigens (OCT-2, BOB.1, CD20) were variably expressed and were weaker in HRS cells than in the background small B cells. T-cell markers (CD3, CD4, and CD8) and EBER by in situ hybridization were negative. Following a diagnosis of cHL, mixed cellularity subtype, chemotherapy was instituted. The skin biopsy demonstrated features characteristic of LyP. It demonstrated a wedge-shaped dermal infiltrate composed of scattered large atypical cells in a mixed inflammatory background composed of small lymphocytes, histiocytes, and eosinophils (Figs. 3C, D) . The epidermis was atrophic, and there was minimal exocytosis and superficial dermal fibrosis. CD30 highlighted the scattered large atypical cells that were also positive for CD3.
Molecular Findings and EBER by In Situ Hybridization
Sufficient material and adequate DNA quality allowed analysis of TRG in all cases with CD30-positive TCL with Hodgkin-like cells, and 9/10 cases studied revealed a clonal rearrangement by TRG. Case 6 had sufficient material for LAM and was further analyzed. Clonal TRG with peaks of identical molecular size were detected in tumor cells from the skin biopsy and in tumor cells from the lymph node biopsy after enrichment using LAM (Figs. 4A, B) . In contrast, a polyclonal TRG was detected from the non-neoplastic background T cells that were microdissected separately from the same lymph node biopsy ( Fig. 4C) .
Two additional cases (cases 3 and 8) had sufficient material to compare the skin and lymph node biopsies by TRG. Whole-mount tissue scrapes were performed, and clonal peaks of identical molecular size were detected by TRG in the skin and lymph node biopsies. TRG performed on the biopsies of cHL and LyP in a single patient (case 11) were noncontributory because of poor DNA quality.
EBER was performed on all cases of CD30-positive TCL with Hodgkin-like cells (10/10), and all were negative. Similarly, EBER was negative in the patient's biopsies with cHL and LyP.
DISCUSSION
Hodgkin-like cells may be encountered in the skin lesions of patients with primary cutaneous CD30-T-LPD, and more rarely in MF, and therefore it is not surprising that when lymph node involvement occurs the process may closely mimic cHL. In addition, better understanding of the nature of these disorders has led to expanded immunophenotypic panels for this distinction, with cHL manifesting evidence of a B-cell lineage with expression of PAX5 in most cases. Thus, older reports of cHL following MF or LyP might not be validated using current criteria, 9, 11, 20, 21, 27 perhaps leading to misconceptions regarding a relationship between these conditions. In this report, we describe 10 patients with MF or CD30-T-LPD who developed nodal disease that resembled cHL; further studies led to a final diagnosis of nodal involvement by CD30-positive TCL with Hodgkin-like cells. In 5 cases a diagnosis of cHL had been made, leading to treatment for cHL in 3 instances.
In the cases of CD30-positive TCL with Hodgkinlike cells, evidence for a T-cell origin was based on expression of T-cell-associated antigens in 7/10 cases and by the demonstration of a clonal T-cell gene rearrangement by PCR in 9/10 cases studied. In case 6 we microdissected the HRS-like cells from the lymph node and showed clonal relationship with the skin lesion diagnosed as LyP, whereas in cases 3 and 8 clonal peaks of the same size were demonstrated in DNA obtained from whole-mount tissue sections of both skin and lymph node lesions by TRG. Although it is difficult to totally exclude occult involvement by the T-cell lymphoproliferative process in a lymph node also involved by cHL as the basis for the T-cell clones, the negativity for PAX5 on the neoplastic cells in these cases both in the skin and lymph nodes argues against the diagnosis of cHL. This conclusion was further substantiated by an absence of a T-cell clone in the background lymphocytes of case 6, not enriched for the large pleomorphic cells.
A CD30-positive, CD15-positive immunophenotype used to be regarded as highly specific for cHL, perhaps leading to misclassification in older reports. More recent studies have shown that some TCLs can show coexpression of both CD30 and CD15. 1, 25 Molecular studies helped to confirm the T-cell lineage in these aggressive TCLs, and absence of staining for PAX5 is an additional useful finding, as most cHL cases express this marker, albeit weakly. 7, 13 Although PAX5 is usually strong evidence for a B-cell lineage, and would favor a diagnosis of cHL, rare cases of ALCL have been reported to express PAX5 secondary to amplification of the PAX5 gene. 6 The case reported by Willenbrock et al 27 may have fallen into this category, as it was reported to show T-cell receptor beta gene rearrangement and was positive for PAX5 as well. The status of the PAX5 gene was not evaluated in that report. Peripheral TCLs can also mimic cHL secondary to EBV-positive Hodgkin-like B cells, but our cases were all EBV negative. 17 One might question whether these cases of CD30positive TCL with Hodgkin-like cells may represent a "T-cell type" of cHL because of the clonal TRG and T-cell antigen expression on the tumor cells. However, lineage is still considered a major factor in the definition of lymphomas, and the current view defines cHL as a tumor of B-cell genotype, albeit with a disordered differentiation profile. 14 Evidence of this disordered differentiation was reported by Tzankov et al 23 in which HRS cells aberrantly expressed T-cell-associated antigens and in rare instances had clonal rearrangement of TCR genes. However, those authors found evidence of B-cell origin as well, with expression of PAX5 or CD20. Disordered differentiation was also observed in some cHL cell lines, which, despite exhibiting some T-cell features, had a gene expression profile similar to that of cHL cell lines with a B-cell phenotype. 28 None of our cases of CD30-positive TCL with Hodgkin-like cells expressed any B-cell-associated markers (ie, CD20, PAX5). Whether a true T-cell form of cHL exists remains controversial, with no confirmed cases since the initial reports in 2000. 16, 18 There were a number of histologic features that proved useful in the distinction of CD30-positive TCL with Hodgkin-like cells from cHL (Table 3 ). In cases of cutaneous CD30-positive TCL, as compared with cHL, the cytoplasm was more basophilic with multiple, usually basophilic nucleoli. Variation in cell size of the HRS-like cells from medium to large was commonly seen as compared with the consistently large size of HRS cells in cHL. The tumor cells often formed cohesive clusters or small sheets, and neoplastic cells showed prominent sinusoidal infiltration (Figs. 1G, 2G ). Even in aggressive variants of cHL, sinusoidal infiltration is rare. Fibrosis was usually evident and variable in extent. Although in half of the cases, the inflammatory background consisted mainly of lymphocytes and histiocytes, in 5 of the cases focal clusters of eosinophils and neutrophils were present. Therefore, this particular finding is not reliable in the distinction between cHL and CD30-positive TCL with Hodgkin-like cells. In fact, 5 cases (cases 3, 4, 7, 8, and 10; Tables 1 and  2) were initially misdiagnosed as cHL. These cases also had a thickened capsule and prominent bands of fibrosis, mimicking cHL, nodular sclerosis subtype.
Patients with both cutaneous TCL and cHL have been described rarely. [2] [3] [4] 9, 11, 12 A few of these case reports ( Table 4 ) described the lymph node tumor as containing sheets of tumor cells, sometimes with a sinusoidal pattern and positive for TRG. 4, 9 We feel that these cases are reminiscent of our 10 cases and likely represent a CD30positive TCL with Hodgkin-like cells rather than cHL. Sinusoidal involvement is not a common feature observed in cHL and likely represents lymph node involvement by the cutaneous TCL.
In the majority of cases of CD30-positive TCL with Hodgkin-like cells (7/10) the nodal lesions were in the lymphatic drainage of the dominant cutaneous lesion, and prominent sinusoidal infiltration also supports lym-phatic invasion as a mode of spread. The single case of cHL and LyP (case 11) had lesions that were distant from each other (skin-left forearm, lymph node-right iliac). We attempted TRG in both specimens of case 11; however, no amplified products were detected in either specimen because of poor DNA quality. Our case of cHL with LyP of the skin was in line with previous case reports in that both lesions were also negative for EBV by EBER in situ hybridization. 2, 10 The case reported by Gellrich et al 8 also found clonal immunoglobulin gene rearrangement in the cHL lymph node but not in the LyP lesions, supporting the diagnosis.
True instances of cHL following a cutaneous TCL are likely rarer than previously described. The distinction between nodal involvement by cutaneous CD30-positive TCL with Hodgkin-like cells and cHL can be extremely difficult. However, with proper immunohistochemical stains, molecular studies, careful examination of the tumor morphology, pattern of infiltration, and thorough clinical history, the distinction between these 2 entities can be made. These cases further emphasize the lack of reliability of the CD30-positive/CD15-positive immunophenotype as pathognomonic for cHL.
